A Real World Study of Apatinib in Treatment of Patients With Gastric Carcinoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03735511

Enrollment

270

Registered

2018-11-08

Start date

2018-11-20

Completion date

2020-08-31

Last updated

2020-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric Carcinoma

Brief summary

The study was designed to evaluate the efficacy and safety of apatinib in the treatment of patients with gastric carcinoma.

Detailed description

The study is a real-world non-interventional retrospective study and will collect the original medical records of patients with gastric carcinoma treated with apatinib from 2015 to 2018 in Henan Cancer Hospital. Clinical data such as patient demographic, history of treatments, tumor biological characteristics and adverse events will be analyzed to evaluate the efficacy and safety of apatinib and explore the risk factors of prognosis in patients with gastric carcinoma.

Interventions

None listed

Study design

Observational model

OTHER

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Pathologically or cytologically confirmed gastric or residual gastric or gastroesophageal junction carcinoma; 2. Patients received apatinib treatment at least once.

Exclusion criteria

1\. No specific

Design outcomes

Primary

Measure	Time frame	Description
Overall Survival	2015-2018	Overall Survival

Secondary

Measure	Time frame	Description
Objective Response Rate	2015-2018	Objective Response Rate
Disease Control Rate	2015-2018	Disease Control Rate
Progression-Free Survival	2015-2018	Progression-Free Survival

Countries

China

Outcome results